Archive for the ‘Personalized Medicine’ Category

EMERYVILLE, Calif.--(BUSINESS WIRE)--

KineMed, Inc. (www.kinemed.com) announced today that David Fineman, KineMed, Inc.s President and CEO will present at the 2012 BIO Investor Forum on Wednesday, October 10th at 11:00 AM PST at the Palace Hotel in San Francisco, CA.

In a talk entitled Pairing Diagnostics with Therapeutics: Biomarker Solutions for Personalized Medicine, Mr. Fineman will share recent developments and breakthrough results from KineMeds powerful kinetic biomarker platform for interrogating the dynamic behavior of the human proteome and lipidome, and discuss how KineMeds exquisitely targeted translational biomarker repertoire is being used as the first functionally interpretable and clinically predictive systems biology platform that can be translated directly into humans.

The timing could not be better for a revolution in biomarker technology, commented Mr. Fineman, The rapid, inexorable shift of pharmaceutical development and patient care towards the Personalized Medicine model means that drugs must be paired with diagnostic biomarkers to enable the right drug to be selected for the right patient at the right time. This requires better targeting of disease subclasses: patient-specific diagnostics, as well as more disease subset-specific therapeutics. KineMeds dynamic signatures translate directly into humans and by virtue of being functionally interpretable and much closer to phenotype than other omics technologies, our measurements offer perhaps the most clinically predictive class of biomarkers yet developed, enabling greater public health benefits and better reimbursement rates for commercial providers.

A webcast of the presentation will be available on Wednesday, October 10th at 12:00 PM PST, one hour after Mr. Finemans live presentation via KineMeds website at http://www.kinemed.com/webcast

About KineMed, Inc.

KineMed, Inc., based in Emeryville, CA, is a drug and disease diagnostic developer, serving pharmaceutical clients and foundations with decision-critical information that accelerates, guides and de-risks drug development, to reduce cost and avoid attrition.KineMed is a partner of choice for drug developers seeking to develop the next generation of medicines that target the underlying causes rather than expressed symptoms of disease and is a field leader in pairing drugs with diagnostic biomarkers that offer Yes/No answers to critical patient management questions: Is this the right drug? Is the drug working?

KineMeds biomarkers are qualitatively and quantitatively different in the answers that they give, compared with other molecular diagnostics, because they are based on kinetic measurements - active measures that compare the rate of biochemical changes between healthy and disease states in a living animal or human. The companys unique, patented isotopic tracer technology tracks dynamic changes in key biochemical pathways that identify the complex biological processes underlying disease to predict clinical outcome. KineMeds biomarkers are fully translational from animal to man, seamlessly harmonizing data across pre-clinical and clinical phases of development, through to the diagnosis and management of diseases including fibrotic, metabolic, cardiovascular disease, and cancer.

KineMeds platform addresses key industry needs:

In addition to assisting clients, KineMed also has an active pipeline of therapeutics and diagnostics in development.

Follow this link:
Pairing Diagnostics with Therapeutics: KineMed to Present Biomarker Solutions for Personalized Medicine at the 2012 ...

NEW YORK & PARIS--(BUSINESS WIRE)--

Bionest Partners, a strategy and management consulting firm for the life science industries, and a leader in personalized medicine (PM) strategy consulting, was invited to participate in the 8th Burrill Personalized Medicine Meeting, a key annual event in the world of PM held at San Francisco on September 13 and 14, 2012.

At the event, Dr. Sean X. Hu, Head of Bionest USA and Managing Partner, the invited speaker from Bionest, hosted a group of senior managers from leading molecular diagnostics (MDx) companies in a panel entitled First Generation PM Companies Where are they now? What can we learn? In addition, Dr. Hu served as an expert host during the Conversations with Experts Luncheon session and shared his expertise on how best to evaluate PM drug and diagnostic product strategies, and, optimize decision-making and implementation.

The panelists shared how their company strategies led to their success to-date, and discussed their views on the key trends and factors in the MDx industry that would impact their future success. Dr. Hu commented: The trend towards PM is inevitable yet remains highly challenging. A great deal of valuable learning emerged from our discussions at this Burrill conference.

For diagnostic companies, it is critical to leverage their core strengths and carefully place their bets by targeting specific unmet clinical needs before, at the time of, or after medical / drug intervention decisions. Depending on whether an MDx company develops a Laboratory-developed test (LDT) or an IVD kit, one must understand and effectively address specific challenges related to its business model, as well as regulatory, pricing, market access and other commercialization aspects across key geo markets.

Dr. Hu continued, For pharmaceutical companies, there is more to PM than simply knowing whether or not and how to incorporate patient stratification biomarkers (as companion diagnostics) into their drugs clinical development and commercialization strategies. Some cutting edge players have already begun to think beyond companion diagnostics and leverage other kinds of Dx products (e.g. disease diagnosis / definition, prognosis etc.) to enhance the value of their drug assets.

Bionest is a powerhouse in PM strategy consulting, serving the pharmaceutical, diagnostics, biotech and medical device industries. It is experienced in addressing a broad spectrum of challenges, from development and commercialization strategies for individual drug assets, diagnostics and other related products, to corporate level PM business models, commercialization capability building, R&D and commercialization business processes, and organizational structure.

Bionest has been driving thought leadership on PM, with many publications on the strategic, commercial and scientific aspects of PM. For more details, please visit http://www.bionest.com, and navigate to section Strategic/Practices/Personalized Medicine Strategy.

For further discussions with Dr. Hu and his Bionest team on PM strategies, please contact him at shu@bionest.com.

About Bionest Partners

Read more from the original source:
Bionest Hosted Discussions at the Burrill Personalized Medicine Conference

The Human Frontier Science Program Organization has awarded Stephen Quake the 2013 Nakasone Award for his work developing technologies in biophysics, biological automation, genome analysis, and personalized medicine. Quake is a professor of bioengineering and a Howard Hughes Medical Institute investigator at Stanford University. He is also a co-founder of Helicos Biosciences and Fluidigm.

Personalized medicine and molecular diagnostics firm Nodality has appointed pharmaceutical, biotech, and venture capital executive Laura Brege to serve as company president and CEO. Brege formerly was executive VP and COO at Onyx Pharmaceuticals, and she was a general partner at Red Rock Capital Management. She also was senior VP and CFO at COR Therapeutics, CFO at Flextronics, and treasurer of The Cooper Companies.

The National Center for Advancing Translational Sciences has named Chris Austin to be the first director of the new center, which launched at the beginning of the year and has so far been run by Acting Director Thomas Insel. Austin began his National Institutes of Health career in 2002, after working as a genomics researcher at Merck, as a senior advisor to the director for translational research at the National Human Genome Research Institute.

See more here:
NantHealth, Blue Shield Partner on Personalized Medicine Venture

BOSTON--(BUSINESS WIRE)--

Third Rock Ventures, LLC, a venture capital firm focused on building life sciences companies, today announced that Felix W. Frueh, Ph.D., has joined Third Rock as an entrepreneur-in-residence (EIR). As an EIR, Dr. Frueh will provide strategic input on new and existing portfolio companies with a particular focus on personalized medicine.

We are pleased to welcome Felix to our growing team of industry leaders, said Alexis Borisy, partner of Third Rock Ventures. Since the founding of Third Rock, we have been dedicated to launching companies focused on personalized medicine, and Felix is the ideal person to help us continue to grow and develop those companies in our portfolio and discover new opportunities to invest in the space.

Dr. Frueh is a thought leader in personalized medicine with 15 years of R&D, management and policy experience. Most recently, Dr. Frueh served as president of the Medco Research Institute, leading Medcos real-world, outcomes-oriented research initiatives and collaborations after having formed Medcos personalized medicine research and development organization. Prior to joining Medco, Dr. Frueh was associate director for genomics at the U.S. Food and Drug Administration (FDA), where he built and led the core genomics review team in the Center for Drug Evaluation and Research (CDER) and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG). Before joining the FDA, he held senior positions at several biotechnology companies. Dr. Frueh has been a member of various working groups on genetics and genomics at the FDA and Department of Health and Human Services (DHHS). He serves on the board of the Personalized Medicine Coalition and is also a board member at Enterome Biosciences. He is an adjunct faculty member at the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina (UNC) and held faculty appointments in the Departments of Pharmacology and Medicine at Georgetown University in Washington, D.C. He was a postdoctoral fellow at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry.

Throughout my career, I have had the opportunity to see new technologies and innovative approaches in personalized medicine make an impact on the lives of patients, said Dr. Frueh. I believe that Third Rocks approach to investing in cutting edge science has the potential to make a tremendous difference, and I look forward to being a part of that effort.

About Third Rock Ventures

Third Rock Ventures is a venture capital firm founded in 2007 with the mission to launch transformative life sciences companies. With more than $800 million and two funds under management, the firm is focused on working with passionate entrepreneurs to build exceptional companies working in areas of disruptive science that will make a difference in the lives of patients. The firm has assembled a team with deep expertise and a proven track record of building respected and successful life sciences companies. With decades of complementary, cross-functional operational and leadership experience, the Third Rock team actively engages with its portfolio companies to provide hands-on strategy and experience to successfully launch companies with the best vision, science, operations, people and culture. With offices in Boston, MA and San Francisco, CA, Third Rock is well positioned geographically to closely collaborate with its portfolio companies to achieve their goals. To learn more about Third Rock and its portfolio companies, please visit http://www.thirdrockventures.com.

Current Third Rock Portfolio Companies

Ablexis, Afferent Pharmaceuticals, Agios Pharmaceuticals, Alcresta, Allena Pharmaceuticals, Alnara Pharmaceuticals (acquired by Eli Lilly & Co. in 2010), bluebird bio, Blueprint Medicines, Constellation Pharmaceuticals, CytomX Therapeutics, DC Devices, Edimer Pharmaceuticals, Eleven Biotherapeutics, Ember Therapeutics, Foundation Medicine, Global Blood Therapeutics, Igenica, Kala Pharmaceuticals, Lotus Tissue Repair, MyoKardia, Nine Point Medical, PanOptica Pharmaceuticals, Rhythm Pharmaceuticals, SAGE Therapeutics, Seventh Sense Biosystems, Taris Biomedical, Topica Pharmaceuticals, Warp Drive Bio and Zafgen.

Read more:
Third Rock Ventures Appoints Personalized Medicine Expert Felix W. Frueh, Ph.D., as Entrepreneur-in-Residence

SAN FRANCISCO, CA--(Marketwire - Oct 1, 2012) - The life sciences sector continued to outperform the broader markets in September, but developments during the month were notable for highlighting the acceleration of the transformation of healthcare through personalized medicine, Burrill & Company says.

"Our healthcare system is dysfunctional and has largely been unchanged through human history in its episodic approach that focuses on treating the symptoms of illness," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm. "Although personalized medicine's transformation of healthcare is an evolutionary rather than a revolutionary process, the events of the past month point to a rapid acceleration of efforts to make medicine personalized, predictive, and pre-emptive and promises to bend the cost-curve of healthcare in a meaningful way."

The University of Texas MD Anderson Cancer Center's announced an ambitious $3 billion Cancer Moon Shots Program, which seeks to develop new diagnostics, devices, drugs, and policies to detect, prevent, and treat cancer by capitalizing on the convergence of low-cost sequencing, artificial intelligence, and other emerging technologies.

September also saw a number of developments on the sequencing front. Chinese sequencing giant BGI-Shenzhen announced a $117.6 million acquisition of the struggling next-generation sequencing company Complete Genomics. Mountain View, California-based Complete Genomics, which has been working to provide whole genome sequencing through a service-based business model, announced a restructuring in June that included a shift in focus to the development of clinical applications for its whole genome sequencing service. BGI-Shenzhen provides deep pockets that should accelerate the clinical applications of Complete Genomic's technology.

Complete Genomics' larger competitors also announced developments that should accelerate the clinical utility of genomic sequencing. Life Technologies began shipping its low-cost Ion Proton sequencing system. The company said the chip-based system cost about a third of genome scale sequencing systems that rely on light to read a genome. The device sits on a desktop and can sequence exomes and transcriptomes in two to four hours at a cost of $1,000 per run. Life Technologies next expects to release a second-generation chip for the system around the end of the first quarter of 2013 that will be able to sequence the human genome in a few hours for $1,000.

At the same time, the genetic sequencing tools company Illumina and the non-profit healthcare system Partners Healthcare announced an agreement to provide geneticists and pathologists networking tools and infrastructure to report and interpret data from genetic sequencing. By pairing Illumina's expertise in sequencing with Partners Healthcare's understanding of what's needed for clinical utility, the two hope to leverage each other's strengths to deliver a comprehensive sequencing and clinical reporting solution.

Others are also taking steps to apply new personalized medicine approaches to clinical care. The Big Data analytics company GNS Healthcare in September announced a new program with the healthcare insurance company Aetna to use GNS' supercomputing capabilities to help identify Aetna members at risk for heart and metabolic disorders that can result in stroke, heart attack or diabetes, earlier than it does today. GNS will develop data-driven models that will define a person's risk for developing metabolic syndrome using Aetna claims data as well as health records. A separate agreement between GNS and the contract research organization Covance seeks to improve drug development by using GNS' modeling to predict the safety and efficacy of a drug candidate against different patient characteristics.

On the research side, September also saw major advances in understanding the genetics underlying disease. The Encode Project, an ambitious international effort to characterize and publish all of the functional elements in the human genome, found that the 80 percent of DNA once thought of as "junk" actually plays a critical role in regulating genes and can also play a part in the onset of disease. Researchers identified more than 4,000 switches involved in gene regulation. The findings not only create a new understanding of the role of some 80 percent of DNA once thought to serve no functional role, but also provide a new source of potential targets for drugs, and new insight into how genes are regulated and how people become ill.

Separately, a collaborative effort funded by the National Cancer Institute and the National Human Genome Research Institute, using data generated as part of The Cancer Genome Atlas, has provided a new understanding of the four major subtypes of breast cancer and finds shared genetic features between the form of breast cancer known as "Basal-like" or "Triple Negative" breast cancer and serious ovarian cancer. The findings will lead to researchers comparing treatments and outcomes for patients with the two forms of cancer and could lead to new therapeutic approaches.

"With new research findings we are reminded about how much we still don't know, but also of the rapid progress we are making," says Burrill. "We are seeing real examples of personalized medicine moving from idea to practice in meaningful ways."

Read more:
Personalized Medicine's Transformation of Healthcare Accelerates

DENVER--(BUSINESS WIRE)--

MPEG LA announced today that Librassay, a landmark collaboration with the National Institutes of Health (NIH) and other leading healthcare innovators (listed below), is now providing one-stop worldwide access to diagnostic discoveries for personalized medicine.

Uncertainties surrounding access to patented technologies have imperiled healthcare advances, said Larry Horn, MPEG LA President and CEO. Just as MPEG LAs origination of patent pools provided a market-based solution for accessing consumer electronics, video and information technologies, now MPEG LAs Librassay introduces a similar solution to the healthcare market with the potential for profound cost savings and quality of life benefits. We applaud the pioneering foresight and efforts of the worlds leading research institutions demonstrating a commitment to their understanding that making world class medical technology widely available is as important as inventing it.

The NIHs policy is to disseminate its technologies as broadly as possible to promote commercialization and improve public health, stated Mark Rohrbaugh, Director of the NIH Office of Technology Transfer. This agreement promotes our policy by permitting MPEG LA and Librassay to pool patented technologies contributed by NIH with complementary technologies from other sources, and to grant non-exclusive, commercial licenses from the pool for in vitro diagnostics and personalized medicine.

Before Librassay, obtaining licenses to medical diagnostic inventions was an ordeal, added Kristin Neuman, Librassay Executive Director. Now Librassay offers one place where diagnostic developers and service providers can obtain assured and affordable access to patent rights, and patent holders have the opportunity for wider adoption of their technologies in combination with others, reasonable compensation for their research investments and the incentive to invest more.

Initial contributors to Librassay include

Starting with some 400 patents, Librassay makes worldwide medical diagnostic patent rights from the worlds leading research institutions available to everyone through a one-stop license. Librassay is expected to be of particular benefit in connection with emerging multiplexed diagnostic tests for disease and other health conditions, including whole genome sequencing, for which patent rights belonging to many different parties may be needed.

MPEG LA welcomes other patent holders to join Librassay. For information, please go to LicensorInfo-Librassay@mpegla.com.

To access the on-line Librassay store, or request a copy of the Librassay Patent Portfolio License, please go to http://www.librassay.com.

MPEG LA, LLC

More here:
MPEG LA’s Librassay® Removes Patent Barriers to Diagnostics for Personalized Medicine

ALISO VIEJO, Calif.--(BUSINESS WIRE)--

Jeffrey Bland, PhD and Metagenics, Inc., a nutrigenomics and lifestyle medicine company focused on improving health and reversing chronic illness, today announced the formation of a new organization, the Personalized Lifestyle Medicine Institute (PLMI). The PLMI, founded by Dr. Bland, will be a not-for-profit organization focused on promoting the importance of personalized lifestyle medicine as the safest and most effective approach to the management of early stages of chronic illness. To help reach its goal of reducing the rising global burden of chronic illness, Metagenics is providing the founding grant to the new organization.

With its rich 30-year history in developing science-based nutritional therapeutics to improve health and reduce chronic illnesses, Metagenics recognizes the years of contribution that Dr. Bland has made to the evolution of the company as its Chief Science Officer, and is the right person to launch this innovative and revolutionary institute, commented Fred Howard, Chief Executive Officer of Metagenics. Forming this institute is an exciting step forward in helping to pave the way for personalized lifestyle medicine to be viewed as a key element in global healthcare systems.

Dr. Bland, who has been the Chief Science Officer for Metagenics for the past 12 years, is an internationally known research scientist and educator in lifestyle and functional medicine. He will lead the Institute in its mission to integrate the principles of personalized lifestyle medicine into healthcare systems around the world.

Dr. Bland brings a unique background as the President of the PLMI:

The PLMI will collaborate with some of the most dedicated and well-regarded thought leaders and decision makers in lifestyle medicine, each to serve an active role in the development of the organization. The PLMI will work to engage researchers, clinicians, health science educators, patient advocacy groups, medical institutions, medical societies, and regulatory and legislative groups to help move its mission forward and further the adoption of lifestyle medicine worldwide. The PLMI will provide educational resources that will facilitate the successful adoption of this approach to the global community through its website (www.plminstitute.org).

I could not be happier to join forces with some of the most dedicated and well-regarded thought leaders and decision makers in the evolving discipline of lifestyle medicine to share information and foster scientific support for this field, said Dr. Bland. This institute will unite researchers, clinicians, health science educators, patient advocacy groups, medical institutions, medical societies, and regulatory and legislative groups to further the adoption of lifestyle medicine.

Within this role and my deep involvement and dedication to educating, publishing and advocacy through the institute, I believe I will make the greatest contribution toward my personal and professional mission: improving health through nutrigenomics and lifestyle medicine, Dr. Bland concluded.

In his new role, Dr. Bland will continue to serve on the Metagenics Board of Directors. He will provide continuing medical education programs sponsored by Metagenics and other organizations that promote the delivery of personalized lifestyle medicine as the best initial approach for the prevention and management of chronic disease.

The PLMI is based in Seattle, WA, and can be reached at 206-922-2915 or info@plminstitute.org.

Follow this link:
Dr. Jeffrey Bland Appointed as President of Newly Formed Personalized Lifestyle Medicine Institute (PLMI)

NEWTON, MA--(Marketwire - Sep 24, 2012) - Recombinant, a provider of data warehousing and clinical intelligence solutions for healthcare performance management, personalized medicine and translational research, will deliver two presentations with client executives from the Northern New England Accountable Care Collaborative (NNEACC) and UCLA Health System at the 20th Annual College of Healthcare Information Management Executives (CHIME) Fall CIO Forum, October 16 - 19 in Indian Wells, CA. Sessions include managing information within an Accountable Care Organization (ACO) model and capitalizing on big data assets. The presentations are part of the Organizational Performance and Emerging Issues in Healthcare and Health Information Technology tracks, respectively. Recombinant is a CHIME Foundation member.

Healthcare Data-as-a-Service for Big Data Challenges

Virginia McFerran, CIO, UCLA Health System, and Jason Oliveira, Managing Director, Health System Consulting, Recombinant, will present "Healthcare Data-as-a-Service for our Big Data Challenges" on Wednesday, October 17 from 11:15 a.m. - 12 p.m. The session will recount the journey of UCLA Health System and its academic partners in strategizing, designing and establishing its xDR data-as-a-service architecture, including best practices and lessons learned.

"Emerging data sources such as EHRs, HIEs, patient portals, and the increasing availability of genomics and proteomics information are pushing health systems into the reality of having to manage massive amounts of data. As more health systems pursue secondary uses of data many quickly realize that they lack an enterprise data management strategy to efficiently exploit their big data assets," said Oliveira. "Virginia and I will help attendees gain a deeper understanding of what managing 'big data' means in terms of new information technology requirements, and what emerging approaches are being taken by the industry by focusing on the experience of our client, UCLA Health System."

Defining and Meeting the Core Data Requirements of ACOs

David Wennberg MD, MPH, Chief Executive Officer, NNEACC, and Mark Golberg, Managing Director, Healthcare Provider ACO, Recombinant will present "Defining and Meeting the Core Data Requirements of ACOs" on Thursday, October 18 from 11:15 a.m. - 12 p.m.

"ACOs cannot deliver on the promise of improving healthcare delivery and patient outcomes and reducing cost without the ability to identify, prioritize, access, and integrate data from internal and external clinical, claims, financial and other critical systems," said Golberg. "The scope, reliability and timeliness of data, in turn, impact downstream applications including knowledge management, decision support, business intelligence, and advanced analytics systems. Dr. Wennberg and I will discuss key issues of ACO data and information management and practical trade-offs often required in ACO network development based on our experience with NNEACC."

"The CHIME Fall CIO Forums combine the best speakers and healthcare IT educators in the nation with unparalleled opportunities for CIOs and healthcare IT executives to network with their peers and collectively share solutions, solve problems and address challenges," said Peter Emerson, Chief Executive Officer, Recombinant. "We are pleased to join with our clients the Northern New England Accountable Care Collaborative and UCLA Health System to share our pragmatic experience and expertise at the 20th CIO Fall Forum."

About Recombinant

Recombinant provides leading-edge data warehousing and clinical intelligence solutions to healthcare providers, academic medical centers and life science researchers to deliver higher quality outcomes, accelerate personalized medicine, and lower costs. Our team of industry veterans is focused on improving the flow of reliable data to power clinical and research applications in a secure, compliant environment. For more information about Recombinant's products and services, visit http://www.recomdata.com.

Read the original here:
Recombinant to Address ACO Data Management and Big Data Opportunities in Healthcare at CHIME12 Fall CIO Forum

NEW YORK, Sept. 24, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Competitive Handbook towards Personalized Medicine in Prostate Cancer

http://www.reportlinker.com/p0980851/Competitive-Handbook-towards-Personalized-Medicine-in-Prostate-Cancer.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, compound types and companies are setting the path?

* How much R&D effort has gone towards different targets and what is known about the target?

* Which pathways are targeted, by what and how?

* What is truly new and unique in the prostate cancer pipeline?

* How new and unique your target strategy really is

* What overlapping competition you have from other companies and compound types towards your therapeutic targets

Follow this link:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

CHATSWORTH, Calif., Sept. 20, 2012 (GLOBE NEWSWIRE) -- IRIS International, Inc. (IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high value personalized medicine solutions today announced that IRIS has received the honor of being asked to speak at two upcoming important meetings: AdvaMedDx's Hill Briefing on "The Role of Advanced Diagnostics in Cancer Care" and the Eighth Annual Summit of the Prostate Health Education Network, Inc.

Cesar M. Garcia, Chairman, President and Chief Executive Officer of IRIS International will present the benefits of NADiA ProsVue, a prognostic prostate cancer test, today at a Capitol Hill briefing sponsored by AdvaMedDx. Held in conjunction with the House Medical Technology Caucus, this briefing will explore how advanced diagnostics are delivering on the promise of personalized medicine. AdvaMedDx represents the world's leading diagnostics manufacturers to advocate for the power of medical diagnostic tests to promote wellness, improve patient outcomes and advance public health in the United States and abroad.

Also today, Dr. Jason Alter, Vice President of Marketing for the Iris Personalized Medicine division will present NADiA ProsVue and advances in prostate cancer prognostic testing at the 8th Annual African American Prostate Cancer Disparity Summit sponsored by the Prostate Health Education Network, Inc. (PHEN) in Washington DC. PHEN is a non-profit organization with a primary mission to increase prostate health education and awareness. The organization focuses on men in the highest risk group for prostate cancer, including African Americans and men with family history.

"We are pleased that important organizations, such as AdvaMedDx and PHEN, are fostering education and understanding of the critical role of diagnostic advances in the management of patients with prostate cancer," said Cesar M. Garcia. "We believe that NADiA ProsVue will be extremely helpful in identifying low risk patients, thus avoiding unnecessary treatments and their resultant side effects, as well as reducing anxiety for patients and costs to the healthcare system."

NADiA ProsVue is an in-vitro diagnostic assay for determining rate of change of serum total prostate specific antigen (tPSA) over a period of time. A retrospective clinical study of 304 patients evaluated the slope of three successive ProsVue tests over a period of at least ten months after a prostatectomy to identify prostate cancer patients with no evidence of disease or clinical progression. Recurrence of disease was determined by positive imaging, biopsy results or prostate cancer related death.

The study resulted in a negative predictive value (NPV), or the proportion of patients correctly identified as stable, of 92.7% and a positive predictive value (PPV), or proportion of patients correctly identified as recurring, of 78.0%. Consequently, a ProsVue slope of equal to or less than 2.0 pg/mL per month in the first year following radical post-prostatectomy was highly associated with no evidence of disease over the long-term follow up.

NADiA ProsVue received 510(k) clearance from the FDA and CE Mark approval in the fall of 2011 and is the first assay to receive FDA clearance based on linear slope of tumor marker concentrations over time. Currently, Iris Personalized Medicine is conducting a Field Experience Trial designed to show how NADiA ProsVue impacts clinical decision-making and potentially optimizes healthcare costs while reducing patient morbidity from unnecessary adjuvant treatment post-radical prostatectomy.

NADiA ProsVue is available through Iris Personalized Medicine's high complexity CLIA-certified laboratory. For more information on NADiA ProsVue, please visit http://www.irispermed.com.

About the NADiA Technology Platform

NADiA technology, Nucleic Acid Detection Immunoassay, is a molecular diagnostics platform targeting the early detection of proteins associated with cancer and infectious diseases utilizing a novel ultra-sensitive and precise method. NADiA combines immunoassay and real-time Polymerase Chain Reaction (PCR) methodologies, or Immuno-PCR, with the potential to detect proteins with femtogram/milliliter sensitivity (10-15 gram/milliliter). As NADiA has the ability to effectively measure extremely low concentrations of proteins, which may be under the detection threshold of current immunoassay methods, it has the potential to provide better therapeutic outcomes for patients.

See the original post here:
IRIS International to Present NADiA ProsVue at Two Important Meetings in Washington DC Addressing the Role of Advanced ...

NEWTON, MA--(Marketwire - Sep 17, 2012) - Jason Oliveira, Managing Director, Health Systems Consulting with Recombinant, a provider of data warehousing and clinical intelligence solutions for healthcare performance management, personalized medicine and translational research, will deliver an online lecture on healthcare performance metrics as part of The College of Healthcare Information Management Executives (CHIME) College LIVE executive education program. The session begins at 12 noon ET on Wednesday, September 19. Registration is limited to CHIME members, but Recombinant has made the content available for download at http://www.recomdata.com/resources_library_presentations.html?=CHIME_PerfMgmt.pdf.

Oliveira has been a strategic advisor to healthcare organizations pursuing their business intelligence planning, technology evaluation, architecture design, and implementation program management efforts for more than 25 years. "Independent of the perceived value of these performance measurement systems as drivers of desirable change, the reality is that they are here; they affect the bottom line; and they are now an operational reality, and burden, to provider organizations," said Oliveira. "My lecture will examine the drivers, requirements, operational impact, and next-generation IT architecture responses for more efficient healthcare performance measurement."

College LIVE is a compelling alternative to traditional, classroom-style education and provides a unique forum for CHIME members to collaborate, interact, and learn. College LIVE presentations focus on healthcare, IT, and executive issues of particular interest to healthcare CIOs.

Performance Measurement Remains a Vexing Problem The convergence of healthcare information technology (HIT), electronic medical records/electronic health records (EMR/EHR), informatics, and data warehousing is helping to surmount the significant data barriers in achieving insight into health system processes, but HIT is not yet making performance measurement easier.Virtually all health care organizations, including providers, payers, pharmaceutical companies, and research organizations suffer from a glut of unstructured and unformatted content, including dictated and transcribed physician notes and scanned documents. Health information is dispersed among multiple operational information systems. Many provider organizations still rely on paper-based legal medical records.

HIT solutions such as physician order entry, clinical documentation, and e-prescribing have improved health care operations and quality, but still require time-consuming performance data capture, measurement, and reporting.Often performance measurement data collection occurs as an additional task for doctors and nurses to conduct, rather than being a by-product of patient care delivery.

While there is promise for facilitating traditional measure sets, as well as new possibilities afforded by HIT, health care organizations are currently still struggling to capture, organize, and utilize performance data.

Solution Pathway The road to pragmatic healthcare performance management begins by determining short- and long-term requirements and identifying gaps with an organization's current methods.The roadmap for optimal movement from the current to the future state will likely include such initiatives as:

In addition, support must be established to empower the accomplishment of these initiatives, primarily through:

These interventions collectively will enable effective performance measurement and ease the burden, cost, and inefficiencies for participating organizations.

About CHIME The College of Healthcare Information Management Executives (CHIME) is an executive organization dedicated to serving chief information officers and other senior healthcare IT leaders. With more than 1,400 CIO members and over 87 healthcare IT vendors and professional services firms, CHIME provides a highly interactive, trusted environment enabling senior professional and industry leaders to collaborate; exchange best practices; address professional development needs; and advocate the effective use of information management to improve the health and healthcare in the communities they serve. For more information, please visit http://www.cio-chime.org.

View post:
Recombinant Executive Jason Oliveira to Present CHIME College Live Session on Healthcare Performance Management

WASHINGTON, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Genomind, LLC, a neuropsychiatric personalized medicine company, recently announced the addition of a new member to its leading Scientific Advisory Board.

Rudolph E. Tanzi, Ph.D., is the director of the Genetics and Aging Research Unit at the MassGeneral Institute for Neurodegenerative Disease in Boston. He is also a professor of neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology and Mental Retardation at Harvard University.

Dr. Tanzi is an internationally respected researcher focusing on the molecular and genetic factors of neurological diseases, with significant interest in Alzheimer's disease. For the last 30 years, he has been dedicated to gene research on neurodegenerative disease and co-discovered the three genes that cause early-onset familial Alzheimer's.

Dr. Tanzi is also responsible for co-discovering genes that trigger Huntington's disease, Wilson's disease, Autism, and other neurological disorders. He is the head of the Alzheimer's Genome Project, a research project of the Cure Alzheimer's Fund, which identified four new related genes - a finding that was named one of the Top Ten Medical Breakthroughs of 2008 by Time magazine. He is the co-author of the book Decoding Darkness: The Search for the Genetic Causes of Alzheimer's Disease, and has co-authored more than 340 articles, making him one of the top ten most cited researchers on Alzheimer's. Dr. Tanzi has been honored with a significant number of awards for his work, which include the Metropolitan Life Foundation Award and The Potamkin Prize.

Dr. Tanzi received his BS from the University of Rochester with a double major in microbiology and history and his Ph.D. in neurobiology from Harvard University.

"It is an honor to welcome Dr. Tanzi to our Scientific Advisory Board," said Genomind Co-founder and Chief Scientific Officer Dr. Jay Lombard. "He is recognized by his peers as the preeminent expert internationally on the genetic basis of Alzheimer's disease pathogenesis. He has dedicated his career to investigating the molecular and genetic causes of Alzheimer's disease, and his discovery of all three genes causing early-onset familial AD is groundbreaking for patients. His discoveries give us hope that there will be more sophisticated ways to develop preventive strategies when diagnosing and treating Alzheimer's disease."

"I am looking forward to working with the Genomind Scientific Advisory Board and the impressive team already in place," said Dr. Tanzi. "Genomind's philosophy of improving patient lives through neurological research aligns perfectly with my research and beliefs, and I hope my past and future findings will help them bring the findings of recent scientific research into real-world use."

Dr. Tanzi joins a distinguished group of thought leaders on the Scientific Advisory Board, all known for their work at the forefront of psychiatric and neurologic research. Board members include Scott T. Aaronson, MD; P. Murali Doraiswamy, MD; Maurizio Fava, MD; Allan I. Levey, MD, PhD; Anil Malhotra, MD; Roy H. Perlis, MD, MSc; and Stephen M. Stahl, MD, PhD.

About Genomind

Genomind is a personalized medicine company comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients' lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

See more here:
Rudolph E. Tanzi, Ph.D. Joins Genomind's Scientific Advisory Board

NEW YORK (GenomeWeb News) The University of Pittburgh today said that it has received two $1 million gifts from The Pittsburgh Foundation to endow chairs for cancer research and personalized medicine.

The gifts will support The Pittsburgh Foundation Endowed Chair in Innovative Cancer Research and The Pittsburgh Foundation Endowed Chair in Personalized Medicine. The non-profit UPMC health system will match the $1 million gift for the personalized medicine chair, the university said.

"With personalized medicine, we aim to move the 'one-size-fits-all' model of medicine to a tailored, 'right-sized' model delivering the right therapy to the right person at the right time," Steven Shapiro, executive vice president and chief medical and scientific officer of UPMC, said in a statement. "If advances in personalized medicine allow physicians to prevent or better treat these diseases based on a patient's genomic profile, the potential savings in human and financial terms could be very significant."

The Pittsburgh Foundation connects donors with charitable organizations and efforts in Pittsburgh and elsewhere in the US.

Excerpt from:
University of Pittsburgh Gets $1M for Personalized Medicine Chair

LONDON (Reuters) - Roche Holding AG, the world's biggest maker of cancer drugs, said it would build on its drive into personalized medicine to hold onto its long-term growth momentum and said it would keep up spending on research and development.

In a statement ahead of a presentation to investors in London on Wednesday, the Swiss drugmaker said it expected 19 late stage trials to read out over the next 18 months.

"More than 60 percent of our pharmaceutical pipeline projects are coupled with the development of companion diagnostics in order to make treatments more effective," Chief Executive Severin Schwan said in a statement.

Roche said it was committed to a stable R&D budget. It spent 8.3 billion Swiss francs ($8.71 billion)on R&D in 2011. The company is also targeting growth in emerging markets as austerity-hit European markets slash healthcare budgets.

(Reporting by Caroline Copley)

Original post:
Roche’s personalized medicine push: 60% of drug pipeline includes companion diagnostic

-- Roche to hold investors meeting in London on Wednesday

-- Personalized Medicine, mid-stage pipeline, R&D spending in focus

-- Updates expected on growth strategy in emerging markets

By Marta Falconi

ZURICH--Roche Holding AG (ROG.VX) will tell investors attending a research-and-development presentation in London next week how it expects to grow by making increased use of its diagnostics unit to develop targeted medicines.

At the London meeting Wednesday, the Swiss drug maker will also showcase highlights from its mid-stage development pipeline, talk about growth in emerging markets and try to reassure investors that it isn't overspending on drug development.

Roche, based in Basel, is the world's sixth-largest pharmaceutical company by sales, according to the latest 2011 figures by pharmaceutical market research company IMS Health Inc. In contrast to many of its peers, sales aren't particularly vulnerable to competition from cheap generics. That is in part because several of its Top 10 drugs are still relatively new, while others are difficult-to-replicate biochemical drugs.

The Swiss drug maker is a darling of analysts, with 17 out of 20 surveyed by Factset giving it a buy rating or equivalent, and only three giving it a hold rating.

Still, Roche needs to convince investors that there is growth beyond the loss of one key patent, that for its third- best selling drug Herceptin, which has become the standard treatment for a certain type of breast cancer. Analysts expect sales of Herceptin to start decreasing from 2015, when the treatment will lose patent protection in Europe. In the U.S., it will lose it in 2019.

Roche has been focusing on developing new drugs to defend its franchise in the treatment of breast cancer, working on products such as Perjeta and T-DM1. Roche is also developing follow-ons to other key cancer drugs, such as Avastin and Rituxan.

Read the original:
Roche to Showcase Personalized Medicine, Mid-Stage Pipeline

IRVINE, Calif. and AMSTERDAM, Aug.29, 2012 /PRNewswire/ --Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, "Present and Future Trends in Breast Cancer Genomics," on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular biologists. The conference is one of several events organized by Agendia throughout the year that brings together research scientists and physicians in clinical practice dedicated to the use and development of molecular diagnostics for cancer treatment.

"Events like these demonstrate why it is an exciting time in the field of medical oncology," said Dr. Stefan Gluck, Chairman of Agendia's Medical Advisory Board. "Breakthrough tools in molecular diagnostics, such as Agendia's MammaPrint, BluePrint and ColoPrint, play an integral role in helping physicians make clinical decisions about how to most effectively treat their patients. Most importantly, these tools are only the beginning of the precision medicine revolution."

The event featured an impressive list of speakers and panels on the following topics:

The Science Behind Genomic Based Analysis of Breast Cancer

Clinical Utility of Molecular Diagnostics

Landmark Clinical Trials

Tumor Round Table Discussion and Case Study Review

"Seventy five percent of cancer therapies today are ineffective," said David Macdonald, CEO of Agendia. "This represents 37 billion dollars spent globally on cancer drugs that do not benefit patients. Today's event further demonstrates Agendia's commitment to the continued development of clinically reliable diagnostics that provide doctors with decision-making tools needed to improve the effectiveness of cancer therapies for their patients."

About Agendia:Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay, and TheraPrint, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

The rest is here:
Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology

Agreement with SureGene Brings Revolutionary Diagnostic Test to Market

LOUISVILLE, Ky.--(BUSINESS WIRE)--SureGene has chosen PGXL as laboratory provider for its proprietary STA2R genetic panel, which promises to revolutionize the treatment of schizophrenia.

PGXL has long been a leader and innovator in personalized medicine. When SureGene needed a lab partner, PGXL was the obvious choice. The synergies from both companies being located in Louisville was an added bonus

The STA2R panel turns intuitive treatment into precision treatment, says Dr. Roland Valdes Jr., Chairman and President of PGXL. It removes the trial and error from the medication of schizophrenia. Its a perfect application of personalized medicine entirely aligned with PGXLs vision.

The STA2R agreement marks the first collaboration between SureGene and PGXL, two companies that spun out of University of Louisville research labs. SureGene researchers discovered and patented the SULT4A1-1 genetic signature. PGXL Laboratories independently developed the STA2R panel and will perform the tests for healthcare providers around the United States. Both SureGene and PGXL are promoting the test, PGXL through its own distribution system and SureGene direct to psychiatric healthcare providers.

PGXL has long been a leader and innovator in personalized medicine. When SureGene needed a lab partner, PGXL was the obvious choice. The synergies from both companies being located in Louisville was an added bonus, says Bill Massey, President of SureGene.

The panel analyzes five genes, including SureGenes patented SULT4A1, and uses the results of those tests to help identify the right treatment path for a patient based on available data. More than 100,000 Americans are diagnosed with schizophrenia every year. While most will eventually be successfully treated, about a third will never find the right balance of medications. The STA2R panel is designed to help guide psychiatrists to that balance quickly and confidently.

Every time I meet with patients and caregivers, they share heart-wrenching stories of their journey to finding the right medicine, says Tim Ramsey, Vice President of SureGene and one of the inventors of STA2R. With STA2R, SureGene and PGXL are giving doctors a powerful new tool to help their patients.

About PGXL Laboratories:

A privately-owned business located in Louisville, Kentucky, PGXL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It offers pharmacogenetic testing, interpretive services, and assay design and validation. Along with its clinical practice, PGXL performs contract research for developers of pharmaceuticals and medical equipment.

See the article here:
PGXL to Provide Antipsychotic Drug Response Tests

ALBANY, New York, Aug. 23, 2012 /PRNewswire/ -- Twease.org - New Report Added in Pharmaceuticals Reports Database Companion Diagnostics and Personalized Medicine Market Report 2012 [http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm]

This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace. Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient populationthe field of stratified medicine.

To Browse Full Toc Visit: http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm [http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm]

Companion Diagnostics has been rapidly expanding over the past 3 years and in this market report we describe the current state of the marketplace from the following perspectives:

Related Reports:

Personalized Medicine Market [http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm]

MicroRNAs and Exosomes Market [http://www.twease.org/report/micrornas-and-exosomes-market-report-2012.htm]

MicroRNA Market [http://www.twease.org/report/microrna-market-trends-2011.htm]

MicroRNA Research and Disease Associations [http://www.twease.org/report/microrna-research-and-disease-associations-2010-market-report.htm]

Circulating Tumor Cells [http://www.twease.org/report/circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-global-industry-size-market-share-trends-analysis-and-forecasts-2012-2018.htm]

More here:
Companion Diagnostics and Personalized Medicine Market Report 2012: Twease.org

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2czp9f/companion_diagnost) has announced the addition of the "Companion Diagnostics and Personalized Medicine Market Report 2012" report to their offering.

This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace. Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient populationthe field of stratified medicine.

Companion Diagnostics has been rapidly expanding over the past 3 years and in this market report we describe the current state of the marketplace from the following perspectives:

- All the Prognostic and Predictive Biomarkers with Potential Clinical Utility are describeda few have already been developed into CDx and we expect growth in this space

- Targeted Therapeutics, Associated Biomarkers, Therapeutic Indications, and Testing Mandates are Described

- Companion Diagnostics Partnerships and Collaborations from 2009 to 2012 are PresentedProvides an Up-to-Date State of the Industry Describing the Disease Areas being Addressed and Types of Biomarkers Being Deployed

- Quantitative Market Metrics

Quantitative Market Forecast: Market Sizing and Growth Rate

Revenue Breakout: Rx versus Dx

The rest is here:
Research and Markets: Companion Diagnostics and Personalized Medicine Market Report 2012

Annual Scientific Meeting of the College of American Pathologists Gives Special Attention to Lung Cancer

Newswise NORTHFIELD, ILL. New science in molecular diagnostics, personalized medicine, and genetic testing for cancer will be featured topics when more than 1,000 pathology leaders gather at the Manchester Grand Hyatt on September 9-12, 2012, for the annual scientific meeting of the College of American Pathologists (CAP). CAP 12THE Pathologists Meeting will highlight advances in anatomic and clinical pathology related to laboratory medicine with a special focus on pulmonary pathology, the diagnosis of lung disease.

Revolutions in the molecular understanding of cancer have changed the way pathologists diagnose this disease and guide treatment, said CAP President Stanley J. Robboy, MD, FCAP. Today, the most effective treatment options are based on appropriate testing, accurate diagnosis, and a team approach to patient care one that includes the pathologist. Weve created a curriculum at our annual meeting for pathologists to keep current on the new diagnostic procedures that can enhance patient care.

At CAP 12, expert pathologists from around the globe will lead educational seminars that provide practical tools, which pathologists can immediately incorporate into their practices. Hot topics include breakthroughs in the molecular testing of lung cancer, a disease that strikes more than 230,000 Americans each year. This special scientific session will offer perspectives from one of the nations leading pathology experts in the study of lung cancer, Marc Ladanyi, MD, FCAP, an attending pathologist on the Molecular Diagnostics Service in the Department of Pathology at Memorial Sloan-Kettering in New York, and Kim Norris, a UCLA Lung SPORE patient advocate and president of the Lung Cancer Foundation of American. Additional hot topics include: o Next-Generation Sequencing for Inherited Disorders o Companion Diagnostics for Targeted Therapy Cancer o Treatment Implication of ER-Positive and HER2-Positive Breast CancerThe Critical Role of Pathologists o Molecular Classification of Multiple Myeloma Using Genomic Profiling

Abstract Program Showcases Junior CAP Members Original Research As part of the CAP 12 Abstract Program, five CAP physician residents will receive special recognition for outstanding original research. Editors from the Archives of Pathology & Laboratory Medicine evaluated the submissions. This years winning abstracts cover a range of topics, including major discrepancies between clinical and postmortem pediatric diagnoses, and a large multi-institutional study that sought to determine whether the 2-tier ovarian serous carcinoma grading system was useful in stratifying these carcinomas.

CAP Will Honor San Diego High School Students for Excellence in Science Additionally, the CAP is honoring six of the best and brightest high school science students in San Diego through its Path to the Future in Medicine program. As part of this program, the students are invited to display their winning projects at CAP 12. In addition, they will have the opportunity to tour the CAP 12 meeting and discuss possible careers in medicine and science, as well as general science issues, with leaders in pathology.

The students, who competed at the 2012 Greater San Diego Science and Engineering Fair in March were judged for excellence in five areas: creativity, scientific thought, attention to detail, skill, and clarity.

The College of American Pathologists (CAP), celebrating 50 years as the gold standard in laboratory accreditation, is a medical society serving more than 18,000 physician members and the global laboratory community. It is the worlds largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care.

### Editors note: Please call Julie Monzo at 847-832-7538, or e-mail jmonzo@cap.org, for free media registration. Or visit our Web site at: http://www.cap.org/CAP12.

Continue reading here:
Advances in Molecular Diagnostics, Genetic Testing, and Personalized Medicine to Be Focus at CAP '12 -- THE ...

The University of Michigan central campus.

ANN ARBOR As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the Phoenix, Ariz.-based International Genomics Consortium have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of the UM Health System and IGC, two leaders in using genetic information to understand and treat disease.

Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.

The company will also help support clinical trials at UMHS and other health systems.

Paradigm complements other DNA services offered by UMHS, including the MLabs reference laboratory, and the research-oriented DNA Sequencing Core. Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships.

The company will be based in Ann Arbor, with additional operations at IGC headquarters in Phoenix.

Were thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes, says Jay Hess, M.D. chair of the Department of Pathology at the UM Medical School and a co-founder of Paradigm. IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision.

Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens, added Robert Penny, M.D., co-founder and CEO of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients.

Initially, Paradigm will focus on offering services to oncologists and oncology groups, pathologists, academic medical centers and clinical trial groups studying personalized medicine regimens. Its first products will be especially of use in better tailoring treatments for cancer patients.

Read the original here:
UM Forms Nonprofit Joint Venture For Personalized Medicine

ANN ARBOR - The University of Michigan and the International Genomics Consortium have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of the U-M Health System and IGC, two leaders in using genetic information to understand and treat disease a step toward providing patients with treatments based on their own DNA profiles.

Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.

The company will also help support clinical trials at UMHS and other health systems.

Paradigm complements other DNA services offered by UMHS, including the MLabs reference laboratory, and the research-oriented DNA Sequencing Core. Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships.

The company will be based in Ann Arbor, with additional operations at IGC headquarters in Phoenix.

"We're thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes," says Jay Hess, M.D. Ph.D., M.H.S.A., chair of the Department of Pathology at the U-M Medical School and a co-founder of Paradigm. "IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision."

"Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens," says Robert Penny, M.D., Ph.D., the chief executive officer and co-founder of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. "We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients."

Initially, Paradigm will focus on offering services to oncologists and oncology groups, pathologists, academic medical centers and clinical trial groups studying personalized medicine regimens. Its first products will be especially of use in better tailoring treatments for cancer patients.

"Pursuing new, innovative channels for scientific collaboration is a priority and strength of the University of Michigan," notes Ora Pescovitz, M.D., CEO of the U-M Health System and U-M executive vice president for medical affairs. "Paradigm is a terrific example of this effort and of how cutting-edge science will have an immediate benefit for patients."

Read the original here:
U-M, International Genomics Consortium Launch Personalized Medicine JV

Public release date: 16-Aug-2012 [ | E-mail | Share ]

Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System

ANN ARBOR, Mich. and PHOENIX, Ariz. As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of the U-M Health System and IGC, two leaders in using genetic information to understand and treat disease.

Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.

The company will also help support clinical trials at UMHS and other health systems.

Paradigm complements other DNA services offered by UMHS, including the MLabs reference laboratory, and the research-oriented DNA Sequencing Core. Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships.

The company will be based in Ann Arbor, with additional operations at IGC headquarters in Phoenix.

"We're thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes," says Jay Hess, M.D. Ph.D., M.H.S.A., chair of the Department of Pathology at the U-M Medical School and a co-founder of Paradigm. "IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision."

"Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens," says Robert Penny, M.D., Ph.D., the chief executive officer and co-founder of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. "We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients."

Read more from the original source:
Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics

Paradigm, formed in partnership with International Genomics Consortium, will help doctors tailor treatment

Newswise ANN ARBOR, Mich. and PHOENIX, Ariz. As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of the U-M Health System and IGC, two leaders in using genetic information to understand and treat disease.

Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.

The company will also help support clinical trials at UMHS and other health systems.

Paradigm complements other DNA services offered by UMHS, including the MLabs reference laboratory, and the research-oriented DNA Sequencing Core. Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships.

The company will be based in Ann Arbor, with additional operations at IGC headquarters in Phoenix.

Were thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes, says Jay Hess, M.D. Ph.D., M.H.S.A., chair of the Department of Pathology at the U-M Medical School and a co-founder of Paradigm. IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision.

Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens, says Robert Penny, M.D., Ph.D., the chief executive officer and co-founder of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients.

Initially, Paradigm will focus on offering services to oncologists and oncology groups, pathologists, academic medical centers and clinical trial groups studying personalized medicine regimens. Its first products will be especially of use in better tailoring treatments for cancer patients.

Read the original post:
Personalized Medicine: U-M Forms New DNA Diagnostics Joint Venture

NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0955290/Personalized-Medicine---A-Global-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

`Personalized Medicine can mean a lot of things to a lot of people. For some, it may relate to doctors having knowledge about their case history and the treatment received, which is a morale boosting factor, since everybody wants caregivers who can comprehend an individual's problems. The day is not very far when this level of personal or individual understanding between a patient and a doctor would be much deeper than hitherto anticipated. The coming decade is expected to witness an increase in the use of companion diagnostics and personalized medicines, with pricing incentives and efficiency improvement propelling the market. Current market leaders with diagnostic divisions focusing on biomarker identification would be at an advantage.

This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.

The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.

This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology. The report covers the brief business profiles of 56 key global players and 77 major players across the United States 45; Europe 24; and Rest of World 8. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION1.1 Product Outline1.1.1 Personalized Medicine's Influence on Large Scale Studies1.1.2 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine1.1.3 Ramifications of Personalized Medicine for Healthcare Systems1.1.3.1 Pharmaceutical Industry1.1.3.2 Diagnostics Industry1.1.3.3 Insurers1.1.3.4 Physicians1.1.3.5 Government Agencies1.1.3.6 Patients1.1.4 Analysis of Personalized Medicine by Segment1.1.4.1 Targeted Biologics1.1.4.1.1 Overview1.1.4.1.2 Targeted Biologics for Breast Cancer: An Illustration1.1.4.2 Proteomics & Genomics1.1.4.2.1 Proteomics1.1.4.2.1.1 A Complex Problem1.1.4.2.1.2 Post-Translational Modifications1.1.4.2.1.3 Phosphorylation1.1.4.2.1.4 Ubiquitination1.1.4.2.1.5 Other Modifications1.1.4.2.2 Genomics1.1.4.2.2.1 Pharmacogenomics1.1.4.3 Genetically Modified (GM) Products1.1.4.3.1 The Genetic Engineering Process1.1.4.3.1.1 Applications of Genetic Engineering1.1.4.4 Wellness & Disease Management1.1.4.4.1 Wellness Defined1.1.4.4.2 Disease Management Defined1.1.4.5 Molecular Diagnostic Technologies1.1.4.5.1 DNA Sequencing1.1.4.5.2 Biochips and Microarrays1.1.4.5.3 Cytogenetics1.1.4.5.3.1 Personalized Medicine Based on Molecular Cytogenetics1.1.4.5.3.2 Personalized Medicine Based on Cytomics1.1.4.5.4 Single Nucleotide Polymorphism (SNP) Genotyping1.1.4.5.4.1 Applications of SNPs Pertinent to Personalized Medicine1.1.4.5.5 Haplotyping1.1.4.5.6 Application of Proteomics In Molecular Diagnosis1.1.4.5.7 Gene Expression Profiling1.1.4.5.8 Personalized Medicine and Molecular Imaging1.1.4.5.9 Diagnostics Based On Glycomics1.1.4.5.10 Combining Diagnostics and Therapeutics1.1.4.5.11 Point-Of-Care (POC) Diagnosis1.1.4.5.12 Genetic Testing For Disease Predisposition1.1.5 Analysis of Personalized Medicine by Technology1.1.5.1 Pharmacogenomics1.1.5.1.1 Drug Metabolism1.1.5.1.2 Applications1.1.5.2 Point-of-Care Testing1.1.5.2.1 Tests that are Most Apt for Specific Scenarios1.1.5.2.2 Advantages1.1.5.3 Stem Cell Therapy1.1.5.3.1 Treatment with Stem Cells1.1.5.3.2 Current Therapies1.1.5.3.3 Future Treatments1.1.5.4 Pharmacoproteomics1.1.5.5 Pharmacogenetics1.1.5.5.1 Prediction of Drug-Drug Interactions1.1.5.5.2 Integration of Pharmacogenetics with the Healthcare System1.1.5.5.3 Pharmacogenetic Tests1.1.5.6 Other Personalized Medicine Technologies1.1.5.6.1 Biochips1.1.5.6.2 Genetic Screening1.1.5.6.3 Metabolomics1.1.5.6.4 Molecular Diagnostics1.1.5.6.5 Pharmacodynamics1.1.5.6.6 Pharmacokinetics1.1.5.6.7 SNP Genotyping1.1.6 The Rationale Behind Personalized Medicine: "One Size no Longer Fits All"1.1.7 The Human Genome: What is It?

2. KEY MARKET TRENDS

Combating Melanoma and Lung Cancer Facilitated Using Novel Personalized Drugs

Read the original post:
Personalized Medicine - A Global Market Overview